Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 30,756,930
  • Shares Outstanding, K 224,250
  • Annual Sales, $ 2,604 M
  • Annual Income, $ 144 M
  • 36-Month Beta 1.40
  • Price/Sales 10.41
  • Price/Book 3.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.54 +19.94%
on 12/19/16
145.00 -6.08%
on 01/10/17
+16.14 (+13.45%)
since 12/16/16
3-Month
109.12 +24.80%
on 12/13/16
145.41 -6.35%
on 11/04/16
+16.71 (+13.99%)
since 10/17/16
52-Week
109.12 +24.80%
on 12/13/16
163.71 -16.82%
on 01/19/16
-22.50 (-14.18%)
since 01/15/16

Most Recent Stories

More News
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ:ALXN)...

Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017

NEW YORK, NY / ACCESSWIRE / January 11, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company")...

Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine

Upcoming AWS Coverage on Jazz Pharmaceuticals

Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 7, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company")...

ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - (ALXN)

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until January 17, 2017 to file lead plaintiff applications...

Company News for January 06, 2017

Companies In The News are: ALXN,CEB,IT,SHLD,SWK,HALO

FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 142.00
1st Resistance Point 139.46
Last Price 135.88
1st Support Level 134.90
2nd Support Level 132.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.